IRIS
BENNETT, DAVID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.769
NA - Nord America 7.078
AS - Asia 2.861
SA - Sud America 537
AF - Africa 76
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.947
IT - Italia 2.035
RU - Federazione Russa 1.786
GB - Regno Unito 1.278
SG - Singapore 938
CN - Cina 929
IE - Irlanda 904
BR - Brasile 463
DE - Germania 420
SE - Svezia 364
HK - Hong Kong 273
FR - Francia 246
UA - Ucraina 227
FI - Finlandia 204
VN - Vietnam 193
IN - India 118
KR - Corea 114
CA - Canada 78
ES - Italia 66
TR - Turchia 51
CZ - Repubblica Ceca 45
PL - Polonia 41
BD - Bangladesh 40
JP - Giappone 38
NL - Olanda 38
MX - Messico 33
AR - Argentina 27
CI - Costa d'Avorio 24
IQ - Iraq 24
AT - Austria 22
ZA - Sudafrica 22
BE - Belgio 21
IR - Iran 16
MA - Marocco 15
UZ - Uzbekistan 14
AU - Australia 13
VE - Venezuela 12
AE - Emirati Arabi Uniti 11
AZ - Azerbaigian 10
EC - Ecuador 10
ID - Indonesia 10
LT - Lituania 10
PK - Pakistan 10
PH - Filippine 9
CH - Svizzera 8
JO - Giordania 8
SA - Arabia Saudita 8
IL - Israele 7
KZ - Kazakistan 7
MK - Macedonia 7
PE - Perù 7
GR - Grecia 6
JM - Giamaica 6
BO - Bolivia 5
DK - Danimarca 5
EG - Egitto 5
PT - Portogallo 5
RO - Romania 5
UY - Uruguay 5
HU - Ungheria 4
KG - Kirghizistan 4
CO - Colombia 3
CR - Costa Rica 3
CY - Cipro 3
EU - Europa 3
LK - Sri Lanka 3
MY - Malesia 3
NO - Norvegia 3
PY - Paraguay 3
AL - Albania 2
AM - Armenia 2
BG - Bulgaria 2
BY - Bielorussia 2
CL - Cile 2
DZ - Algeria 2
GD - Grenada 2
HN - Honduras 2
KE - Kenya 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NP - Nepal 2
PA - Panama 2
SN - Senegal 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GI - Gibilterra 1
GT - Guatemala 1
HR - Croazia 1
IM - Isola di Man 1
Totale 18.323
Salva come PNG Salva come JPEG
Città #
Dallas 1.401
Southend 1.108
Dublin 888
Singapore 614
Fairfield 578
Ashburn 536
Moscow 526
Chandler 442
Santa Clara 388
Siena 284
Beijing 282
Hong Kong 264
Woodbridge 254
Seattle 215
Wilmington 208
Ann Arbor 200
Cambridge 183
Jacksonville 179
Houston 178
Milan 173
Munich 165
Hefei 150
New York 144
Los Angeles 130
Florence 123
Princeton 120
Seoul 112
Helsinki 109
Boardman 58
Rome 58
Dearborn 54
Nanjing 53
Buffalo 50
Dong Ket 50
Chicago 49
The Dalles 49
Turku 47
Ho Chi Minh City 46
Shanghai 44
London 43
Fremont 42
Málaga 42
São Paulo 38
San Mateo 37
Tokyo 37
Catania 35
Nuremberg 34
Warsaw 34
Hanoi 30
Bengaluru 28
Menlo Park 26
San Diego 26
Abidjan 24
Izmir 24
Brno 23
Düsseldorf 23
Frankfurt am Main 23
Atlanta 22
Toronto 22
Brussels 21
Council Bluffs 21
Denver 21
Lauterbourg 21
Montreal 21
Nanchang 20
Washington 20
Chennai 19
Columbus 19
Olomouc 19
Poplar 19
Redondo Beach 19
Brooklyn 18
Guangzhou 18
Lastra a Signa 18
San Francisco 18
Shenyang 18
Gavirate 17
Orem 17
Changsha 16
Johannesburg 16
Lappeenranta 16
Mumbai 16
Padova 16
Phoenix 16
Boston 14
Hebei 14
Brescia 13
Norwalk 13
San Jose 13
Trieste 13
Messina 12
Paris 12
Portsmouth 12
Tashkent 12
Arezzo 11
Clifton 11
Jiaxing 11
Manchester 11
Mexico City 11
Miami 11
Totale 11.779
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.025
A first update on mapping the human genetic architecture of COVID-19 542
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 356
Antirheumatic agents in covid-19: is IL-6 the right target? 333
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 331
An explainable model of host genetic interactions linked to COVID-19 severity 327
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 320
Peripheral biomarkers' panel for severe COVID-19 patients 292
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 287
Exhaled nitric oxide in interstitial lung diseases 252
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 250
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 248
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 247
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 246
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 243
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 242
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 237
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 236
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 233
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 231
Bronchial stenosis following lung transplant: An innovative approach with a modified endobronchial emphysema valve 229
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 228
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 224
Serum amyloid A in patients with idiopathic pulmonary fibrosis 223
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 221
Prognostic bioindicators in severe COVID-19 patients 220
Diffuse panbronchiolitis in a patient with common variable immunodeficiency: a casual association or a pathogenetic correlation? 219
Serial KL-6 measurements in COVID-19 patients 215
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 214
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 211
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 203
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 201
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 198
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 198
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 193
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 193
SARS-CoV-2 in pleural fluid in a kidney transplant patient 191
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 190
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 189
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 188
Extracorporeal Photopheresis in Lung Transplantation 188
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review 185
WES profiling of COVID-19 184
Biomarkers in sarcoidosis: The contribution of system biology 182
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 182
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 181
Proteomic investigation of pulmonary sarcoidosis 179
Coronavirus HKU 1 infection with bronchiolitis, pericardial effusion and acute respiratory failure in obese adult female 178
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 175
IPF mortality in waiting list for lung transplantation 171
Impact of SARS-CoV-2 outbreak on heart and lung transplant: a patient-perspective survey 171
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 169
Anti-Cytosolic 5′-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study 167
Chitotriosidase: a sensitive biomarker of sarcoidosis 166
BIOMARKERS WITH CLINICAL SIGNIFICANCE IN PATIENTS WITH INTERSTITIAL LUNG DISEASES 165
null 165
Helicobacter pylori antibody positivity in idiopathic pulmonary fibrosis 163
Mortalità in lista per trapianto di polmone in pazienti affetti da fibrosi polmonare idiopatica 162
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 161
Familial pulmonary fibrosis: Clinical-functional and radiological features 156
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study 156
New concepts in the pathogenesis of sarcoidosis 155
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 152
Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis 150
IPFdatabase - A new tool for a correct application of idiopathic pulmonaty fibrosis guidelines 147
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 147
Whole-genome sequencing reveals host factors underlying critical COVID-19 146
Rischio infettivo nel trapianto di polmone per fibrosi polmonare: analisi retrospettiva 146
null 145
Comparative proteomic analysis of bronchoalveolar lavage of familial and sporadic cases of idiopathic pulmonary fibrosis 143
Outcome of ECMO bridge to lung transplantation: a single cohort study 137
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant 135
Valutazione dell'ossido nitrico nell'esalato delle polmoniti interstiziali idiopatiche 134
The Role of Galectins in Chronic Lung Allograft Dysfunction 133
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study 132
Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction 129
Exhaled nitric oxide and carbon monoxide in lung transplanted patients 124
null 121
Immune checkpoint analysis of T-cell responses to pp65 and IE-1 antigens in end-stage lung diseases 120
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 119
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective 117
Pulse oximetry oxyhemoglobin saturation in patients with idiopathic pulmonary fibrosis 115
Cavernous sinus syndrome due to neurosarcoidosis in adolescence: a diagnosis not to be missed 114
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 112
null 106
Relapses of idiopathic inflammatory myopathies after vaccination against COVID19: a real-life Italian study 105
Donor-Recipient Mismatch in Lung Transplantation: The Role of Graft Sizing in Clinical Outcomes 98
Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP 97
NK and T cells responses to CMV in patients awaiting for lung transplantation 96
Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review 95
NK and T cell in patients with end-stage lung disorders waiting for lung transplantation in response to CMV infection 93
Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience 92
Calgranulin B/S100A9 and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP 83
Lung transplantation in patients with previous or unknown oncological disease: evaluation of short- and long-term outcomes 82
Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity 82
Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo‐Controlled 6‐Minute Walk Test Study 74
Erratum: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis (Respiratory Research (2020) 21 (6) DOI: 10.1186/s12931-019-1263-z) 68
Assessing Short- and Medium-Term Outcomes of Lung Transplantation in Elderly Recipients: A Comparative Age-Based Analysis 50
A novel web-based tool for lung transplant patients undergoing extracorporeal photopheresis 48
Esperienza in real-life della terapia con Pirfenidone in pazienti affetti da IPF. 37
Totale 18.611
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.100
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.040 0 0 0 0 0 194 104 201 138 148 132 123
2021/20221.230 93 153 86 97 71 47 57 72 50 118 146 240
2022/20231.799 145 187 195 225 152 266 157 151 154 74 57 36
2023/20241.752 76 49 179 89 80 408 532 67 15 48 51 158
2024/20253.150 108 161 417 152 371 198 169 164 199 139 355 717
2025/20265.723 553 993 1.186 1.053 1.687 251 0 0 0 0 0 0
Totale 18.692